Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features.

Drug screening studies typically involve assaying the sensitivity of a range of cancer cell lines across an array of anti-cancer therapeutics. Alongside these sensitivity measurements high dimensional molecular characterizations of the cell lines are typically available, including gene expression, copy number variation and genomic mutations. We propose a sparse multitask regression model which learns discriminative latent characteristics that predict drug sensitivity and are associated with specific molecular features. We use ideas from Bayesian nonparametrics to automatically infer the appropriate number of these latent characteristics. The resulting analysis couples high predictive performance with interpretability since each latent characteristic involves a typically small set of drugs, cell lines and genomic features. Our model uncovers a number of drug-gene sensitivity associations missed by single gene analyses. We functionally validate one such novel association: that increased expression of the cell-cycle regulator C/EBPδ decreases sensitivity to the histone deacetylase (HDAC) inhibitor panobinostat.

Abstract licence: CC BY

1. 6.

   A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation · 2006

2. 28.

   Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties · 2013

3. 33.

   Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200 · 2014

4. 42.

   Dose-Response Analysis Using R · 2015

5. 44.

   A Landscape of Pharmacogenomic Interactions in Cancer · 2016

46 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.